NSCLC

AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer

Ajmal Aseem 25 June 2025

AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.

Cancer Healthcare & Pharmaceuticals News Regulatory Approval

AbbVie’s EMRELIS™ (telisotuzumab vedotin-tllv) Receives U.S. FDA’s Accelerated Approval for Adults With Small Cell Lung Cancer (NSCLC)

Ajmal Aseem 15 May 2025

EMRELIS™ (telisotuzumab vedotin-tllv) used for previously treated adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression.